Means and Methods to Regulate Gut Dysbiosis

Patent metadata

Field	Value
Publication number	US-2024382506-A1
Application number	US-202218570876-A
Country	US
Kind code	A1
Filing date	Jun 20, 2022
Priority date	Jun 18, 2021
Publication date	Nov 21, 2024
Grant date	—

Abstract

The present invention relates to the field of microbial growth, more specifically microbial overgrowth, even more specifically overgrowth of Enterobacteriaceae, specifically under conditions of apoptosis in the gut such as IBD, colitis, chemotherapy and food borne bacterial infections. The present invention provides inhibitors of a bacterial target, pyruvate formate lyase, which can be used to regulate the overgrowth of Enterobacteriacea.

First claim

1 . An inhibitor of functional expression of a pyruvate formate lyase, wherein the inhibitor is selected from an antisense oligonucleotide, a gapmer, a shRNA, a siRNA, a CRISPR, a TALEN, or a Zinc-finger nuclease.

2 . The inhibitor of functional expression of pyruvate formate lyase of claim 1 , wherein the inhibitor is comprised in a medicament.

3 . A method of treating a gut disease in subject characterized by excessive apoptosis occurs, the method comprising: administering to the subject the inhibitor of functional expression of pyruvate formate lyase of claim 1 .

4 . The method according to claim 3 , wherein the gut disease is associated with colitis, inflammatory bowel disease, chemotherapy induced mucositis, or bacterial infection.

5 . The method according to claim 4 , wherein the bacterial infection is an enterobacterial infection.

6 . The method according to claim 5 , wherein the enterobacterial infection is a food-borne infection.

7 . The method according to claim 6 , wherein the enterobacterial food-borne infection is is an infection of a Klebsiella species, Escherichia species, or Salmonella species.

Assignees

• Vib Vzw
• Univ Gent

Inventors

• Ravichandran Kodimangalam
• Anderson Christopher

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/7036

  having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins · CPC title

• A61P1/00 Primary

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title